Abstract Details

Title Mapping Vibratory Sensory Loss Across MS Disease Course

Topic Multiple Sclerosis

Presentation(s) S54 - Multiple Sclerosis: Disease Progression, Disease-modifying Therapy, and Clinical Considerations (4:18 PM-4:30 PM)

Poster/Presentation
Number 005

Objective To determine whether a quantitative measure of vibratory sensation captures sensory dysfunction across multiple sclerosis (MS) disease course and test a model of neurological dysfunction accumulation from outset.

Background

MS is predominantly conceptualized as a dichotomous process, with early relapsing phase due to inflammation and later progressive accumulation of disability driven by neurodegeneration. Increasing data suggest neuroinflammation and neurodegeneration occur in parallel in early phase and throughout the disease course. Ability to measure initial accumulation of neurological dysfunction will refine the MS disease model and support investigation of treatments. We previously reported impaired vibratory sensation among asymptomatic 1^st degree relatives (of MS patients) at higher risk of developing MS than those with lower risk and healthy volunteers (HV). Here we extend observations to MS patients to map a continuum of accumulated sensory dysfunction across disease course.

Design/Methods In this cross-sectional study, we measured vibratory sensation in 80 MS patients using the Vibratron-II device. Results were pooled with those contemporaneously obtained from HV without family history of MS (n=53) and 1^st degree family members (of MS patients) with risk score for MS susceptibility (GERS_MS) calculated based on genetic burden and environmental exposures (n=41 higher-risk, n=59 lower-risk).

Results MS patients were grouped into Low (0-2; n=54), Intermediate (2.5-5.5; n=7) and High (6-8; n=19) EDSS. All MS groups had measurable impairment of vibratory sensation compared to HV. Higher risk GERS_MS and Low EDSS MS were not statistically different. Representing MS progression as a continuum from Low to High EDSS, impaired vibratory sensation correlates with disease course (r_s 0.76, p <0.001).

Conclusions Quantitative measurement of vibratory sensation maps accumulation of neurological dysfunction in MS. Preclinical detection may aid the development of interventions to prevent overt disease accumulation. Longitudinal follow-up is warranted.

Authors/Disclosures
Nigar Dargah-Zada, MD (Complete Neurological Care) PRESENTER	Dr. Dargah-Zada has nothing to disclose.
Sonya U. Steele, MD (Johns Hopkins University)	No disclosure on file
	No disclosure on file
Gina Norato	No disclosure on file
	No disclosure on file
	No disclosure on file
Joan M. Ohayon (National Institutes of Health)	Joan M. Ohayon has nothing to disclose.
Zongqi Xia, MD, PhD	The institution of Dr. Xia has received research support from National Institute of Health. The institution of Dr. Xia has received research support from Department of Defense. The institution of Dr. Xia has received research support from Genentech/Roche.
Philip De Jager, MD, PhD (Columbia University Irving Medical Center)	Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. De Jager has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Puretech. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for roche. Dr. De Jager has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. The institution of Dr. De Jager has received research support from roche. The institution of Dr. De Jager has received research support from Biogen. The institution of Dr. De Jager has received research support from puretech.
Daniel Reich, MD, PhD (National Institutes of Health, Neuroimmunology Branch, NINDS)	Dr. Reich has received research support from NIH. The institution of Dr. Reich has received research support from Adelson Medical Research Foundation. The institution of Dr. Reich has received research support from Sanofi. The institution of Dr. Reich has received research support from Abata Therapeutics. The institution of Dr. Reich has received research support from National Multiple Sclerosis Society. Dr. Reich has received intellectual property interests from a discovery or technology relating to health care. Dr. Reich has received personal compensation in the range of $5,000-$9,999 for serving as a CME Faculty with PeerView. Dr. Reich has received personal compensation in the range of $5,000-$9,999 for serving as a CME Faculty with Integrity. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with Letters and Sciences. Dr. Reich has received personal compensation in the range of $500-$4,999 for serving as a CME Faculty with Academic CME. Dr. Reich has a non-compensated relationship as a Advisor with Sanofi that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Board of Directors with ACTRIMS that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Abata Therapeutics that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with University of Basel RC2NB that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Multiple Sclerosis Society of Canada that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Tuscan Doctorate in Neuroscience that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Editorial Board with Multiple Sclerosis Journal that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Biohaven that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Sana that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Merck KGaA EMD Serono that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Bristol-Meyers Squibb that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with ChemoCentryx that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator, Advisor with Hyperfine that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Imaginab that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Perceptive that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Annexon that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator, Advisor with Philips that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Siemens that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Novartis that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Calico Life Sciences that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Cognito Therapeutics that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Sudo that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with Allumis that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with BioCentury that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Regeneron that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Collaborator with Eli Lilly that is relevant to AAN interests or activities. Dr. Reich has a non-compensated relationship as a Advisor with SetPoint that is relevant to AAN interests or activities.
Irene Cortese, MD	Dr. Cortese has stock in Keires, AG. Dr. Cortese has stock in Nouscom, AG. Dr. Cortese has stock in PDC*line Pharma.

��ɫ��

��ɫ��